These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 22882002)

  • 1. Generation and evaluation of bispecific affibody molecules for simultaneous targeting of EGFR and HER2.
    Ekerljung L; Wållberg H; Sohrabian A; Andersson K; Friedman M; Frejd FY; Ståhl S; Gedda L
    Bioconjug Chem; 2012 Sep; 23(9):1802-11. PubMed ID: 22882002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engineering and characterization of a bispecific HER2 x EGFR-binding affibody molecule.
    Friedman M; Lindström S; Ekerljung L; Andersson-Svahn H; Carlsson J; Brismar H; Gedda L; Frejd FY; Ståhl S
    Biotechnol Appl Biochem; 2009 Aug; 54(2):121-31. PubMed ID: 19492986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension.
    Malm M; Bass T; Gudmundsdotter L; Lord M; Frejd FY; Ståhl S; Löfblom J
    Biotechnol J; 2014 Sep; 9(9):1215-22. PubMed ID: 24678002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
    Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
    Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design of an optimized scaffold for affibody molecules.
    Feldwisch J; Tolmachev V; Lendel C; Herne N; Sjöberg A; Larsson B; Rosik D; Lindqvist E; Fant G; Höidén-Guthenberg I; Galli J; Jonasson P; Abrahmsén L
    J Mol Biol; 2010 Apr; 398(2):232-47. PubMed ID: 20226194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IgM CH2 domain as covalently linked homodimerization module for the generation of fusion proteins with dual specificity.
    Seifert O; Plappert A; Heidel N; Fellermeier S; Messerschmidt SK; Richter F; Kontermann RE
    Protein Eng Des Sel; 2012 Oct; 25(10):603-12. PubMed ID: 22988132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor.
    Friedman M; Nordberg E; Höidén-Guthenberg I; Brismar H; Adams GP; Nilsson FY; Carlsson J; Ståhl S
    Protein Eng Des Sel; 2007 Apr; 20(4):189-99. PubMed ID: 17452435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A bispecific transmembrane antibody simultaneously targeting intra- and extracellular epitopes of the epidermal growth factor receptor inhibits receptor activation and tumor cell growth.
    Müller N; Hartmann C; Genssler S; Koch J; Kinner A; Grez M; Wels WS
    Int J Cancer; 2014 Jun; 134(11):2547-59. PubMed ID: 24243620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Affinity recovery of eight HER2-binding affibody variants using an anti-idiotypic affibody molecule as capture ligand.
    Wållberg H; Löfdahl PK; Tschapalda K; Uhlén M; Tolmachev V; Nygren PK; Ståhl S
    Protein Expr Purif; 2011 Mar; 76(1):127-35. PubMed ID: 21029777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule.
    Friedman M; Orlova A; Johansson E; Eriksson TL; Höidén-Guthenberg I; Tolmachev V; Nilsson FY; Ståhl S
    J Mol Biol; 2008 Mar; 376(5):1388-402. PubMed ID: 18207161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a trispecific antibody conjugate that directs two distinct tumor-associated antigens to CD64 on myeloid effector cells.
    Somasundaram C; Sundarapandiyan K; Keler T; Deo YM; Graziano RF
    Hum Antibodies; 1999; 9(1):47-54. PubMed ID: 10331185
    [TBL] [Abstract][Full Text] [Related]  

  • 13. (99m)Tc-maEEE-Z(HER2:342), an Affibody molecule-based tracer for the detection of HER2 expression in malignant tumors.
    Tran T; Engfeldt T; Orlova A; Sandström M; Feldwisch J; Abrahmsén L; Wennborg A; Tolmachev V; Karlström AE
    Bioconjug Chem; 2007; 18(6):1956-64. PubMed ID: 17944527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB; Adams GP; Weiner LM; Marks JD
    Cancer Res; 2000 Nov; 60(22):6434-40. PubMed ID: 11103810
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
    Biburger M; Weth R; Wels WS
    J Mol Biol; 2005 Mar; 346(5):1299-311. PubMed ID: 15713482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemically generated IgG2 bispecific antibodies through disulfide bridging.
    Patterson JT; Gros E; Zhou H; Atassi G; Kerwin L; Carmody L; Zhu T; Jones B; Fu Y; Kaufmann GF
    Bioorg Med Chem Lett; 2017 Aug; 27(16):3647-3652. PubMed ID: 28720505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.
    Vernet E; Konrad A; Lundberg E; Nygren PA; Gräslund T
    J Immunol Methods; 2008 Sep; 338(1-2):1-6. PubMed ID: 18671978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of variable domain orientation and arrangement on the antigen-binding activity of a recombinant human bispecific diabody.
    Lu D; Jimenez X; Witte L; Zhu Z
    Biochem Biophys Res Commun; 2004 May; 318(2):507-13. PubMed ID: 15120630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Small sized EGFR1 and HER2 specific bifunctional antibody for targeted cancer therapy.
    Ding L; Tian C; Feng S; Fida G; Zhang C; Ma Y; Ai G; Achilefu S; Gu Y
    Theranostics; 2015; 5(4):378-98. PubMed ID: 25699098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.